Placebo effect in clinical trial design for irritable bowel syndrome

Journal of Neurogastroenterology and Motility

Volumn 20, Issue 2, 2014, Pages 163-170

  Shah, Eric ^a   Pimentel, Mark ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Clinical trial; Irritable bowel syndrome; Placebos

Indexed keywords

ALOSETRON; CATECHOL METHYLTRANSFERASE; DESIPRAMINE; KETOROLAC; NALOXONE; OPIATE; OPIATE ANTAGONIST; PLACEBO; RIFAXIMIN;

COHORT ANALYSIS; CONDITIONED REFLEX; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DOPAMINE RELEASE; DRUG RESPONSE; EXPERIMENTAL THERAPY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC MARKER; HUMAN; IRRITABLE COLON; MOTOR PERFORMANCE; NEUROBIOLOGY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PLACEBO EFFECT; PSYCHOLOGICAL THEORY; REVIEW; TREATMENT RESPONSE; WEAKNESS;

EID: 84897487012     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm.2014.20.2.163     Document Type: Review

References (63)

1. Bernstein CN. The placebo effect for gastroenterology: tool or torment. Clin Gastroenterol Hepatol 2006;4:1302-1308.
2. Enck P, Bingel U, Schedlowski M, Rief W. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov 2013;12:191-204.
3. Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010;32:144-158.
4. Beecher HK. The powerful placebo. J Am Med Assoc 1955;159: 1602-1606.
5. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev 2010;(1):CD003974.
6. Duracinsky M, Chassany O. [How can an effective drug to treat irritable bowel syndrome be successfully developed?]. Gastroenterol Clin Biol 2009;33(suppl 1):S26-S34. [French]
7. Kienle GS, Kiene H. Placebo effect and placebo concept: a critical methodological and conceptual analysis of reports on the magnitude of the placebo effect. Altern Ther Health Med 1996;2:39-54.
8. Moerman DE, Jonas WB. Deconstructing the placebo effect and finding the meaning response. Ann Intern Med 2002;136:471-476.
9. Marshall JK, Thabane M, Garg AX, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 2010;59:605-611.
10. Olafsdottir LB, Gudjonsson H, Jonsdottir HH, Thjodleifsson B. Stability of the irritable bowel syndrome and subgroups as measured by three diagnostic criteria - a 10-year follow-up study. Aliment Pharmacol Ther 2010;32:670-680.
11. Morton V, Torgerson DJ. Regression to the mean: treatment effect without the intervention. J Eval Clin Pract 2005;11:59-65.
12. Witt CM, Schützler L. The gap between results from sham-controlled trials and trials using other controls in acupuncture research - the influence of context. Complement Ther Med 2013;21:112-114.
13. Patel SM, Stason WB, Legedza A, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005;17:332-340.
14. Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:237-247.
15. Berger VW, Rezvani A, Makarewicz VA. Direct effect on validity of response run-in selection in clinical trials. Control Clin Trials 2003; 24:156-166.
16. Lee HF, Hsieh JC, Lu CL, et al. Enhanced affect/cognition-related brain responses during visceral placebo analgesia in irritable bowel syndrome patients. Pain 2012;153:1301-1310.
17. Morton DL, Watson A, El-Deredy W, Jones AK. Reproducibility of placebo analgesia: Effect of dispositional optimism. Pain 2009;146: 194-198. 18. Kelley JM, Lembo AJ, Ablon JS, et al. Patient and practitioner influences on the placebo effect in irritable bowel syndrome. Psychosom Med 2009;71:789-797.
18. Kelley JM, Lembo AJ, Ablon JS, et al. Patient and practitioner influences on the placebo effect in irritable bowel syndrome. Psychosom Med 2009;71:789-797
19. Dorn SD, Kaptchuk TJ, Park JB, et al. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterol Motil 2007;19:630-637.
20. Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet 1978;2:654-657.
21. Nolan TA, Price DD, Caudle RM, Murphy NP, Neubert JK. Placebo-induced analgesia in an operant pain model in rats. Pain 2012;153:2009-2016.
22. Benedetti F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 1996;64:535-543.
23. Eippert F, Bingel U, Schoell ED, et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 2009;63:533-543.
24. Petrovic P, Kalso E, Petersson KM, Andersson J, Fransson P, Ingvar M. A prefrontal non-opioid mechanism in placebo analgesia. Pain 2010;150:59-65.
25. Vase L, Robinson ME, Verne GN, Price DD. Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain 2005;115:338-347.
26. de la Fuente-Fernández R. The placebo-reward hypothesis: dopamine and the placebo effect. Parkinsonism Relat Disord 2009;15 (suppl 3):S72-S74.
27. Hall KT, Lembo AJ, Kirsch I, et al. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One 2012;7:e48135.
28. Bryant CD, Roberts KW, Culbertson CS, Le A, Evans CJ, Fanselow MS. Pavlovian conditioning of multiple opioid-like responses in mice. Drug Alcohol Depend 2009;103:74-83.
29. Stewart-Williams S, Podd J. The placebo effect: dissolving the expectancy versus conditioning debate. Psychol Bull 2004;130:324-340.
30. Watson A, El-Deredy W, Iannetti GD, et al. Placebo conditioning and placebo analgesia modulate a common brain network during pain anticipation and perception. Pain 2009;145:24-30.
31. Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry 2013;170:723-733.
32. Amanzio M, Pollo A, Maggi G, Benedetti F. Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain 2001;90:205-215.
33. Vase L, Riley JL 3rd, Price DD. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain 2002; 99:443-452.
34. Benedetti F, Pollo A, Lopiano L, Lanotte M, Vighetti S, Rainero I. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 2003;23: 4315-4323.
35. Kotsis V, Benson S, Bingel U, et al. Perceived treatment group affects behavioral and neural responses to visceral pain in a deceptive placebo study. Neurogastroenterol Motil 2012;24:935, e462.
36. Kaptchuk TJ, Friedlander E, Kelley JM, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010;5:e15591.
37. Naliboff BD, Berman S, Suyenobu B, et al. Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. Gastroenterology 2006;131:352-365.
38. Kim SE, Kubomoto S, Chua K, Amichai MM, Pimentel M. "Pre-cebo": an unrecognized issue in the interpretation of adequate relief during irritable bowel syndrome drug trials. J Clin Gastroenterol 2012;46:686-690.
39. Britten N. Patients' ideas about medicines: a qualitative study in a general practice population. Br J Gen Pract 1994;44:465-468.
40. Macfarlane J, Holmes W, Macfarlane R, Britten N. Influence of patients' expectations on antibiotic management of acute lower respiratory tract illness in general practice: questionnaire study. BMJ 1997;315: 1211-1214.
41. Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning- activated specific subsystems. J Neurosci 1999;19:484-494.
42. Montgomery GH, Kirsch I. Classical conditioning and the placebo effect. Pain 1997;72:107-113.
43. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104(suppl 1):S1-S35.
44. Hani AA, Shah ED, Pimentel M. Sa1158 The number of drug side effects is associated with greater efficacy in IBS clinical trials: the potential influence of unblinding. Gastroenterology 2013;144(supple 1): S-217.
45. Mangel AW, Hahn BA, Heath AT, et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res 1998;26:76-81.
46. Müller-Lissner S, Koch G, Talley NJ, et al. Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol 2003;56:310-316.
47. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377-1390.
48. Corsetti M, Tack J. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterol Motil 2013;25:453-457.
49. Fallone CA, Guyatt GH, Armstrong D, et al. Do physicians correctly assess patient symptom severity in gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2004;20:1161-1169.
50. Whitehead WE, Palsson OS, Levy RL, Feld AD, VonKorff M, Turner M. Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol 2006;101:1057-1065.
51. Passos MC, Lembo AJ, Conboy LA, et al. Adequate relief in a treatment trial with IBS patients: a prospective assessment. Am J Gastroenterol 2009;104:912-919.
52. Spiegel B, Camilleri M, Bolus R, et al. Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. Gastroenterology 2009; 137:1944-1953, e1-e3.
53. Wechsler ME, Kelley JM, Boyd IO, et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med 2011;365:119-126.
54. 3 receptor antagonist. Aliment Pharmacol Ther 1999;13:1149- 1159.
55. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355:1035-1040.
56. Shah E, Kim S, Chong K, Lembo A, Pimentel M. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med 2012;125:381-393.
57. Committee for Medicinal Products for Human Use (CHMP). Concept paper on the revision of the CHMP points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome (CPMP/EWP/785/97). European Medicines Agency, May 2012. Available from URL: http://www.ema.europa. eu/docs/en_GB/document_library/Scientific_guideline/2012/06/ WC500128217.pdf (accessed 23 January, 2014).
58. Center for Drug Evaluation and Research (CDER). Guidance for industry: irritable bowel syndrome - clinical evaluation of drugs for treatment. Food and Drug Administration, May 2012. Available from URL: http://www.fda.gov/downloads/Drugs/Guidances/UCM205269. pdf (accessed 23 January, 2014).
59. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012;107:1714-1724.
60. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107:1702-1712.
61. Macdougall JE, Johnston JM, Lavins BJ, et al. An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. Neurogastroenterol Motil 2013; 25:481-486.
62. Shah ED, Pimentel M. 1039 Functional Net Value (FNV): an Important Consideration in Clinical Evaluation of IBS Pharmacotherapy. Gastroenterology 2012;142(suppl 1):S-182.
63. Lucak SL. Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. Therap Adv Gastroenterol 2010;3:165-172.